EB-003

❧

Wikipedia

EB-003
Clinical data
Other namesEB003
Drug classNon-hallucinogenic serotonin receptor agonist; Psychoplastogen; Neurostabilogen

EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][3][4][5] It is a tryptamine[1][5] and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT).[3]

The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptors.[1][3][4][5] It is not a serotonin 5-HT2B receptor agonist.[5][6] EB-003 produces psychoplastogenic effects.[3][4][5] Due to targeting not only the serotonin 5-HT2A receptor but also the serotonin 5-HT1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer.[3]

EB-003 is being developed by Enveric Biosciences.[1][2] As of February 2025, it is in the preclinical research stage of development.[1][2] A phase 1 clinical trial is being planned.[1] The drug's exact chemical structure does not yet seem to have been disclosed.[1][5] It has been patented, though the patent does not yet appear to have been published.[7]

See also

References

  1. 1 2 3 4 5 6 7 "EB-003 - Enveric Biosciences". AdisInsight. 6 February 2025. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on EB-003(Enveric Biosciences) with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. 1 2 3 4 5 Roberts, Madison (28 August 2025). "AbbVie's $1B Psychedelic Bet: Who's Next in the Neuroplastogen Gold Rush?". Microdose. Retrieved 22 October 2025.
  4. 1 2 3 "Pipeline – Enveric Biosciences". Enveric Biosciences. Retrieved 16 February 2025.
  5. 1 2 3 4 5 6 "Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series". Financial Post. BusinessWire. 28 December 2023. Retrieved 16 February 2025.
  6. ↑ "Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003". ENVB Stock News. 15 October 2024. Retrieved 16 February 2025.
  7. ↑ "Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office". Yahoo Finance. 30 January 2025. Retrieved 16 February 2025.